Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity
出版年份 2020 全文链接
标题
Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity
作者
关键词
-
出版物
EXPERIMENTAL AND MOLECULAR MEDICINE
Volume 52, Issue 9, Pages 1475-1485
出版商
Springer Science and Business Media LLC
发表日期
2020-09-11
DOI
10.1038/s12276-020-00500-y
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial
- (2019) Vicky Makker et al. LANCET ONCOLOGY
- Normalizing Function of Tumor Vessels: Progress, Opportunities, and Challenges
- (2019) John D. Martin et al. Annual Review of Physiology
- The Intersection between Tumor Angiogenesis and Immune Suppression
- (2019) Osama E. Rahma et al. CLINICAL CANCER RESEARCH
- Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP-002 study.
- (2019) Josep M Llovet et al. JOURNAL OF CLINICAL ONCOLOGY
- TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion
- (2019) Omar Khan et al. NATURE
- T Cell Dysfunction in Cancer Immunity and Immunotherapy
- (2019) Anliang Xia et al. Frontiers in Immunology
- Dual PD ‐1 and VEGFR ‐2 blockade promotes vascular normalization and enhances anti‐tumor immune responses in HCC
- (2019) Kohei Shigeta et al. HEPATOLOGY
- STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade
- (2019) Hannah Yang et al. JOURNAL OF CLINICAL INVESTIGATION
- LBA3IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)
- (2019) A-L Cheng et al. ANNALS OF ONCOLOGY
- Tumor angiogenesis: causes, consequences, challenges and opportunities
- (2019) Roberta Lugano et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- VEGF-A drives TOX-dependent T cell exhaustion in anti–PD-1–resistant microsatellite stable colorectal cancers
- (2019) Chang Gon Kim et al. Science Immunology
- Increased vessel perfusion predicts the efficacy of immune checkpoint blockade
- (2018) Xichen Zheng et al. JOURNAL OF CLINICAL INVESTIGATION
- Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
- (2018) Dai Fukumura et al. Nature Reviews Clinical Oncology
- Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
- (2018) Kabir A. Khan et al. Nature Reviews Clinical Oncology
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- Defining the role of the tumor vasculature in antitumor immunity and immunotherapy
- (2018) Marco B. Schaaf et al. Cell Death & Disease
- Contribution to Tumor Angiogenesis From Innate Immune Cells Within the Tumor Microenvironment: Implications for Immunotherapy
- (2018) Adriana Albini et al. Frontiers in Immunology
- Safety and clinical activity of 1L atezolizumab + bevacizumab in a phase Ib study in hepatocellular carcinoma (HCC).
- (2018) Stacey Stein et al. JOURNAL OF CLINICAL ONCOLOGY
- Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy
- (2017) Keehoon Jung et al. JOURNAL OF CLINICAL INVESTIGATION
- Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming
- (2017) Lin Tian et al. NATURE
- Tumour ischaemia by interferon-γ resembles physiological blood vessel regression
- (2017) Thomas Kammertoens et al. NATURE
- Targeting CXCR4-dependent immunosuppressive Ly6Clowmonocytes improves antiangiogenic therapy in colorectal cancer
- (2017) Keehoon Jung et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade
- (2017) Martina Schmittnaegel et al. Science Translational Medicine
- Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation
- (2017) Elizabeth Allen et al. Science Translational Medicine
- Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC
- (2017) Paul C. Tumeh et al. Cancer Immunology Research
- Normalization of Tumor Vessels by Tie2 Activation and Ang2 Inhibition Enhances Drug Delivery and Produces a Favorable Tumor Microenvironment
- (2016) Jin-Sung Park et al. CANCER CELL
- Suppression of microRNA activity amplifies IFN-γ-induced macrophage activation and promotes anti-tumour immunity
- (2016) Caroline Baer et al. NATURE CELL BIOLOGY
- Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients
- (2016) Mizuki Nishino et al. Journal for ImmunoTherapy of Cancer
- Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy
- (2015) R. Hughes et al. CANCER RESEARCH
- Intertwined regulation of angiogenesis and immunity by myeloid cells
- (2015) Lee B. Rivera et al. TRENDS IN IMMUNOLOGY
- Intratumoral Myeloid Cells Regulate Responsiveness and Resistance to Antiangiogenic Therapy
- (2015) Lee B. Rivera et al. Cell Reports
- Clodronate inhibits tumor angiogenesis in mouse models of ovarian cancer
- (2014) Nicole M Reusser et al. CANCER BIOLOGY & THERAPY
- Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
- (2014) Rakesh K. Jain CANCER CELL
- Vascular RhoJ Is an Effective and Selective Target for Tumor Angiogenesis and Vascular Disruption
- (2014) Chan Kim et al. CANCER CELL
- Novel Glycosylated VEGF Decoy Receptor Fusion Protein, VEGF-Grab, Efficiently Suppresses Tumor Angiogenesis and Progression
- (2014) J.-E. Lee et al. MOLECULAR CANCER THERAPEUTICS
- Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors
- (2014) Gregory T Motz et al. NATURE MEDICINE
- Orchestration of Angiogenesis by Immune Cells
- (2014) Antonino Bruno et al. Frontiers in Oncology
- The Impact of the Immune System on Tumor: Angiogenesis and Vascular Remodeling
- (2014) Christian Stockmann et al. Frontiers in Oncology
- A Mechanism of Hypoxia-Mediated Escape from Adaptive Immunity in Cancer Cells
- (2013) I. B. Barsoum et al. CANCER RESEARCH
- Angiopoietin-2: An Attractive Target for Improved Antiangiogenic Tumor Therapy
- (2013) D. Gerald et al. CANCER RESEARCH
- The tumor microenvironment at a glance
- (2013) F. R. Balkwill et al. JOURNAL OF CELL SCIENCE
- T-Regulatory Cells: Key Players in Tumor Immune Escape and Angiogenesis
- (2012) A. Facciabene et al. CANCER RESEARCH
- The discovery of placenta growth factor and its biological activity
- (2012) Sandro De Falco EXPERIMENTAL AND MOLECULAR MEDICINE
- Macrophage plasticity and polarization in tissue repair and remodelling
- (2012) Alberto Mantovani et al. JOURNAL OF PATHOLOGY
- Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy
- (2012) Y. Huang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma
- (2011) Jiankun Liu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Targeting the ANG2/TIE2 Axis Inhibits Tumor Growth and Metastasis by Impairing Angiogenesis and Disabling Rebounds of Proangiogenic Myeloid Cells
- (2011) Roberta Mazzieri et al. CANCER CELL
- M2 Macrophages Induced by Prostaglandin E2 and IL-6 from Cervical Carcinoma Are Switched to Activated M1 Macrophages by CD4+ Th1 Cells
- (2011) M. Heusinkveld et al. JOURNAL OF IMMUNOLOGY
- Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
- (2011) Andrea Facciabene et al. NATURE
- Macrophage Diversity Enhances Tumor Progression and Metastasis
- (2010) Bin-Zhi Qian et al. CELL
- Transforming growth factor-β and the hallmarks of cancer
- (2010) Maozhen Tian et al. CELLULAR SIGNALLING
- Origin and development of dendritic cells
- (2010) Kang Liu et al. IMMUNOLOGICAL REVIEWS
- Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
- (2010) Subhra K Biswas et al. NATURE IMMUNOLOGY
- Effect of classification based on combination of mutation and methylation in colorectal cancer prognosis
- (2010) Iida ONCOLOGY REPORTS
- CD4+ T Cells Regulate Pulmonary Metastasis of Mammary Carcinomas by Enhancing Protumor Properties of Macrophages
- (2009) David G. DeNardo et al. CANCER CELL
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
- (2009) Marta Pàez-Ribes et al. CANCER CELL
- Tumor-Targeted Interferon-α Delivery by Tie2-Expressing Monocytes Inhibits Tumor Growth and Metastasis
- (2008) Michele De Palma et al. CANCER CELL
- TGF-β signaling in vascular biology and dysfunction
- (2008) Marie-José Goumans et al. CELL RESEARCH
- Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis
- (2008) Christian Stockmann et al. NATURE
- Orchestrating the orchestrators: chemokines in control of T cell traffic
- (2008) Shannon K Bromley et al. NATURE IMMUNOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started